IPP Bureau
Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags
By IPP Bureau - August 12, 2025
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Lupin partners with Sadoz to commercialise Ranibizumab biosimilar
By IPP Bureau - August 12, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial
By IPP Bureau - August 12, 2025
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
By IPP Bureau - August 12, 2025
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
By IPP Bureau - August 12, 2025
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad
By IPP Bureau - August 11, 2025
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Lupin launches Glucagon for Injection USP, 1mg/Vial in US
By IPP Bureau - August 11, 2025
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP
By IPP Bureau - August 11, 2025
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
By IPP Bureau - August 11, 2025
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr
By IPP Bureau - August 11, 2025
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
By IPP Bureau - August 11, 2025
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr
By IPP Bureau - August 11, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
By IPP Bureau - August 10, 2025
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr
By IPP Bureau - August 10, 2025
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
